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Background: IDH mutations frequently occur in diffuse gliomas and result in a neo-enzymatic activity that results
in reduction of α-ketoglutarate to D-2-hydroxyglutarate. In gliomas, the frequency of IDH1 mutations in codon 132
increases in the order R132L-R132S-R132G-R132C-R132H with R132H constituting more than 90% of all IDH1 mutations.
Results: We determined the levels of D-2-hydroxyglutarate in glioma tissues with IDH1 mutations. D-2-hydroxyglutarate
levels increased in the order of R132H-R132C-R132S/R132G/R132L. We expressed and purified IDH1 wild type and
mutant protein for biochemical characterization. Enzyme kinetics of mutant IDH protein correlated well with D-2-hydro-
xyglutarate production in cells with R132H exhibiting the highest and R132L the lowest KM for α-ketoglutarate. Addition
of D-2-hydroxyglutarate to the medium of cell lines revealed an inhibitory effect at higher concentrations. Migration of
LN229 increased at lower D-2-hydroxyglutarate concentrations while higher concentrations showed no effect.
Conclusion: These findings may suggest natural selection against the rare IDH1R132 mutations in human glioma due to
toxicity caused by high levels of D-2-hydroxyglutarate.
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Mutations in isocitrate dehydrogenases 1 or 2 (IDH1,
IDH2) occur approximately in 75% of diffuse astrocyto-
mas and oligodendroglial tumors [1-3], in 20% of acute
myeloid leukemia (AML) [4,5], 50% of chondrosarcoma
[6,7], 20% of intrahepatic cholangiocarcinoma [8] and
in 20% of angioimmunoblastic T-cell lymphoma [9]. Be-
sides overall frequency, also the type of IDH mutations
differs in these tumor entities. In astrocytoma and oligo-
dendroglioma more than 90% of all IDH mutations
are of the IDH1R132H type [2], with the second most
frequent type (approximately 4% of mutations) being* Correspondence: Andreas.vonDeimling@med.uni-heidelberg.de
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stated.IDH1R132C. The remaining mutations split into other
very rare IDH1 and IDH2 mutations. Quite differently,
IDH2R140Q mutations are most frequent in AML [5,10].
In chondrosarcoma and intrahepatic cholangiocarcinoma,
the R132C alteration in IDH1 is the most frequent muta-
tion [6,8], while in angioimmunoblastic T-cell lymphoma
mutations in IDH2 are predominant [9]. Common to
all IDH mutations is a neo-enzymatic activity of the mu-
tated proteins that results in reduction of α-ketoglutarate
(α-KG) to D-2-hydroxyglutarate (2-HG) with consump-
tion of NADPH. The neo-enzymatic activity of mutated
IDH proteins is believed to constitute the major tumori-
genic mechanism of this alteration due to the inhibitory
effect of 2-HG on α-KG dependent dioxygenases. Among
these, the TET hydroxylases are affected resulting in a se-
verely altered methylation pattern of DNA [11,12] confer-
ring an unknown advantage to these tumor cells.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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higher 2-HG levels in rare IDH1 mutations than in the
most common IDH1R132H alteration [13]. A similar
observation was made for IDH2, with cells carrying mu-
tations affecting R172 exhibiting higher 2-HG concen-
trations than those with mutations in R140 [14]. These
findings suggest different enzyme activity grades for the
variant IDH mutants.
To explore the potential role of different mutation
types in the formation of astrocytomas and oligodendro-
glial tumors, we determined the enzyme kinetics of wild
type IDH1 and with the mutations R132H, R132C,
R132G, R132S, R132L and R100Q followed by quantifi-
cation of 2-HG in transfected cells and in human tumor
tissues, and examined the effects on viability.
Methods
FFPE samples, DNA extraction and IDH1 sequencing
The collection of IDH1 mutant tumors consist out of
previously published specimen [1,2,15] and tumors col-
lected at the neuropathology department of the patho-
logical institute of Heidelberg.
The DNA extractions form FFPE samples were per-
formed by hand using Invisorb Genomic DNA Kit II (Invi-
tek, Berlin, Germany) or semi-automated using Maxwell®
16 FFPE Plus LEV DNA Purification Kit (Promega, Madi-
son, USA) following the manufacturer’s protocol.
The sequencing of published specimen was performed
as described in the earlier publications. Our most recent
probes were sequenced by generating a fragment of
212 bp length spanning the catalytic domain of IDH1 in-
cluding codon 100 and 132 using 60 ng each of the sense
primer IDH1-JM_f TGATGAGAAGAGGGTTGAGGA
and the antisense primer IDH1-JM_r GCAAAATCACAT
TATTGCCAAC. PCR using standard buffer conditions,
20 ng of DNA and GoTaq DNA Polymerase (Promega,
Madison, USA) employed 35 cycles with denaturing at
95°C for 30 s, annealing at 57°C for 40 s and extension at
72°C for 50 s in a total volume of 15 μl.
A total of 2 μl of the PCR amplification product was
submitted to the sequencing reaction using the BigDye
Terminator v3.1 Sequencing Kit (Applied Biosystems,
Foster City, USA). Twenty-five cycles were performed
employing 12 ng of the sense primer IDH1-JM_f TGAT
GAGAAGAGGGTTGAGGA, with denaturing at 95°C
for 30 s, annealing at 57°C for 15 s and extension at
60°C for 240 s. A second round of sequencing analysis
was performed using the antisense primer IDH1-JM_r
GCAAAATCACATTATTGCCAAC and the sequencing
reaction conditions as described above. Sequences were
determined using the semi-automated sequencer (ABI
3100 Genetic Analyzer, Applied Biosystems, Foster City)
and the Sequence Pilot version 3.1 (JSI-Medisys, Kippen-
heim, Germany) software.IDH1 mutant generation and cloning
IDH1 mutants were generated using the site directed mu-
tagenesis method. Therefore, primers for each mutation
were created and used on IDH1 wt cDNA in pDONR221
(DKFZ clone repository). Each mutation was confirmed by
Sanger sequencing using the same procedure as described
for the FFPE samples. The pDONR221 clones were used
for all further LR-reactions into the described destination
vectors. LR-reactions were performed following the manu-
facturers protocol (Invitrogen, Carlsbad, USA).
IDH1 protein purification
To purify the different IDH1 proteins, the cDNAs were
transferred into pDEST15 (Invitrogen, Carlsbad, USA),
an E. coli expression vector containing a N-terminal
GST tag (Invitrogen, Carlsbad, USA). The pDEST15 vec-
tors were then transfected into E.coli expression strain
KRX (Promega, Madison, USA). The E.coli were then
streaked out on lysogeny broth (LB)-plates containing
Ampicillin (100 μg/ml, Sigma-Aldrich, St. Luis, USA)
and incubated at 37°C overnight. Six clones from each
construct were transferred into 6 ml liquid LB contain-
ing 100 μg/ml Ampicillin and grown over night at 37°C
in an orbital shaker (220 rpm). From these overnight
cultures we used aliquots to prepare two small cultures
(10 ml) for induction experiments. We only induced one
culture from each colony following the manufacturer’s
protocol (KRX protocol, Promega, Madison, USA). Briefly,
inoculation of 1:100 of overnight culture, two hours incu-
bation at 37°C and 220 rpm in the orbital shaker followed
by the induction with 0.1% L-Rhamnose (10% stock solu-
tion in water, AppliChem, Gatersleben, Germany) and
four hours incubation at RT and 220 rpm. Subsequently
both cultures of each clone were harvested by centrifuga-
tion and resuspendet in GST-Lysis buffer from the Pierce®
GST Spin Purification Kit (Thermo Scientific, Rockford,
USA). Then they went through three freeze-thaw cycles
with liquid nitrogen and a 15 min sonification step,
followed by a 15 min centrifugation at 5000 rpm on 4°C.
The supernatant was used for a SDS-PAGE (Invitrogen,
Carlsbad, USA). A coomassie stain of the gel showed us
which colonies yield best results. We then used these
clones according to the protocol described above to pre-
pare 200 ml cultures. The supernatant of these cultures
were then used for protein purification with the Pierce®
GST Spin Purification Kit (Thermo Scientific, Rockford,
USA), following the manufacturer’s protocol.
IDH1 enzyme kinetics
The measurement of the enzyme kinetics was performed
with an Omega FluoStar (BMG Labtech, Ortenberg,
Germany) equipped with a pump system, which was
used to start the reaction, by adding 4 μg protein to the
reaction mixture. All measurements were performed in
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total volume of 100 μl at 37°C. The reaction mixture
consisted of Tris–HCl pH 7.4 (50 mM), MgCl2 (2 mM),
NaCl (10 mM), BSA (0.05%), NADP+/NAPDH (10 mM
or concentration row), and isocitrate/α-KG (10 mM or
concentration row). As a negative control we used the
same mixture, but without isocitrate or α-KG, depending
on the KM to be obtained. After the start of the reaction,
a one second double orbital shaking (500 rpm) was used
to mix the reaction. Thereafter, every two minutes data
was obtained from each well measuring the NADPH
production or consumption (Ex. 340 +/− 10 nm, Em.
440 +/− 10 nm), depending on the reaction analyzed.
All measurements were done in triplicate and at least
15 data points of each reaction were used for KM cal-
culation. The mean of three independent measure-
ments and the standard deviation of these is plotted
for each KM.
D-2-hydroxyglutarate
The 2-HG detection was performed with an enzymatic
assay developed in our lab. Probe preparations and mea-
surements were performed as described in [16].
D-2-hydroxyglutarate was obtained from Sigma Aldrich
(St. Luis, USA) as disodium salt (catalogue number H8378).
Octyl-D-2-hydroxyglutarate was synthesized following
the method reported by Xu et al. [12] with slight modifica-
tions (detailed protocol for D-2-hydroxyglutarate synthe-
sis, see Additional file 1 and Additional file 2: Figure S1).
Cell lines
All cell lines were achieved from the ATCC and cultured
under standard culture conditions (37°C, 5% CO2) in
DMEM medium with 1% Penicillin and Streptomycin
and 10% fetal calf serum (all obtained from Gibco® Invi-
trogen, Carlsbad, USA).
For the generation of IDH1R132H overexpressing
cells, IDH1R132H in the destination vector pDEST26
(N-terminal 6x His Tag) was used. LN229 cells were
transfected with IDH1R132H in pDEST26 vector by
Fugene 6 (Promega, Madison, USA) followed by picking
of single cell clones. Single cell clones were selected
with 2 mg/ml Gentamycin (Invitrogen, Carlsbad, USA).
Clones that survived selection were analyzed for their
expression of IDH1R132H by western blot. Clones H3
and H114 were chosen for further analysis, due to their
different and stable expression levels of IDH1R132H.
For all experiments with the inducible expression
system we used normal cell culture medium, but ex-
changed normal FCS with 10% Tet system approved FBS
(Clontech, Mountain View, USA). To generate an indu-
cible cell line we used the pT-REx-DEST system (Invi-
trogen, Carlsbad, USA). As a first step we transfected
the cell line LN319 with pcDNA6/TR. From thistransfection we generated single cell clones and tested their
reliability by introducing EGFP in pT-REx-DEST30. We
chose the clone with no GFP expression in tetracycline free
media and with the highest expression after induction with
1 μM Doxycycline (Sigma-Aldrich, St. Luis, USA). This
clone 09 (K09) was then used for all further experiments.
For the experimental setup we used LN319 K09 trans-
fected with IDH1 wild type (wt), the different IDH1 mu-
tants, and GFP in pT-REx-DEST30. All cell lines were
seeded as described under proliferation analysis. For
each cell line two triplicates were seeded. One was in-
duced with 1 μg/ml Doxycycline, the other one was
treated with the comparable amount of solvent (DMSO,
Sigma-Aldrich, St. Luis, USA).
To generate cell lines which express IDH1 wt and mu-
tant proteins, we used cDNAs in pMXs-GW-IRES-BsdR
and transfected them into HEK293T cells with FuGene®.
Cells were subsequently put under selection pressure, by
adding 4 μg/ml Blasticidine S (Sigma-Aldrich, St. Luis,
USA). As control we used GFP in pMXs-GW-IRES-BsdR.
Cell line analysis
For cell number analysis CellTiterGlo (Promega, Madison,
USA) was used in 96-well plate format. All cells were
seeded at a density of 5,000 cells/well and subsequently
treated. Measurements were performed at the indicated
time points following the manufacturer’s protocol.
All migration assays were performed with Ibidis
Culture-Inserts. In each well of the insert, 50,000 cells
were seeded. After 24 h, the cells were treated with
10 μg/ml Mitomycin C (Sigma-Aldrich, St. Luis, USA)
for 2 h, to avoid the influence of proliferation in the
assay. Afterward, the inserts were removed leaving a
gap of 500 μm +/− 50 μm. Cells were washed with PBS
once and thereafter normal medium was applied. This
medium was subsequently substituted with 2-HG at the
given concentrations. The gap was microscopically docu-
mented at the start and the indicated time points. The
pictures were analyzed with TScratch (http://chaton.
ethz.ch/software/) and the area closed after the indicated
time point was plotted in the graph.
The soft agar assays were performed in 6-well plates.
The wells were prepared with a 1% agar solution (Agar
noble, US Biological, Salem, USA) as base agar. On top
of this, 5,000 cells in 0.35% agar were seeded and grown
for 14 days. The cells were stained with 0.00025% crystal
violet solution and colonies > 1 mm2 were counted.
Results
Distribution of IDH1 mutations in gliomas
Including data from a previous study [2] and on ongoing
routine analysis of all diffuse astrocytoma and oligo-
dendroglioma in the Department of Neuropathology at
the University Heidelberg, the present series of IDH1



























Figure 1 Distribution of IDH1 mutation types. Distribution of mutation types in the Heidelberg series of 1,976 diffuse astrocytomas and
oligodendrogliomas with IDH1 mutations.
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These 1,976 tumors represent only the immunohisto-
chemical and sequence verified IDH1 mutant cases out
of the whole collection of glial tumors in our depart-
ment. The frequency of IDH1 mutations in these tumors
decreases in the order R132H (91.5%), R132C (4.3%),
R132G (1.9%), R132S (1.6%), R132L (0.6%) and R100Q
(0.3%). Incidences of the mutations are given in Figure 1.
2-HG in tumor tissue
We determined the amount of 2-HG in glioma tissue.

























Figure 2 D-2-hydroxyglutarate levels in FFPE tissue. D-2-hydroxyglutara
with IDH1 mutations. Shown are the levels of 6 IDH1 wt tumors, 25 with IDH1R
show significant (** = p≤ 0.01) higher 2-HG levels than wildtype tumors, but o
significant (* = p≤ 0.05).of IDH1 mutations in gliomas other than R132H. Suffi-
cient formalin fixed and paraffin embedded tissue was
available from 9 tumors with R132C, 6 tumors with
R132G and 1 each with R132S and R132L. Due to loss
of 2-HG during the processing up to paraffin embedding
[13], only approximate values for 2-HG could be deter-
mined. Lowest 2-HG levels were detected in tumors
with R132H followed by R132C and then R132G. The
single tumors with R132S and R132L mutation also ex-
hibited high levels of 2-HG. No 2-HG was detected in 5
control glioma samples without IDH1 mutation. The
data is shown in Figure 2.R132C R132G
*
te levels in FFPE tissue from diffuse astrocytomas and oligodendrogliomas
132H, 8 with IDH1R132C and 7 with IDH1R132G. All mutant tumors
nly the difference between R132H and R132G mutation was statistically
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Recombinant expression of proteins with IDH1 muta-
tions followed by purification enabled the determination
of Michaelis constants for each mutant protein with the
substrate α-KG. A high KM of α-KG was observed for
the R132H mutation (243.7 μM) whereas lower KM’s
were seen for R132G (67.4 μM), R132C (33.7 μM),
R132S (26.1 μM) and R132L (11.8 μM). Data is shown in
Figure 3A.
The very rare R100Q mutation exhibited a high KM
of (3671.1 μM). This was the only mutated IDH1 pro-
tein for which a Michaelis constant for isocitrate wasFigure 3 KM values and D-2-hydroxyglutarate levels of IDH1 mutation
isocitrate (B). The KM value for α-ketoglutarate of IDH1 wt and the KM value
Therefore KM values of R132 mutations are not shown. All KM values are sig
not otherwise stated (* = p≤ 0.05 or n.s. = not significant). All measuremen
xyglutarate levels in HEK293T cells ectopically expressing different IDH1 mutatio
confluent dish of 6-well Plate 72 h after seeding. All D-2-hydroxyglutarate level
than both controls (wt and GFP). The levels of all other R132 mutants are signi
** = p≤ 0.01). Only the level of R100Q is significant lower than the level of R13detected (KM = 2724.0 μM) (Figures 3A and 3B). To fur-
ther validate this data, we transfected HEK293T cells
with all different IDH1 variants and determined the
cellular 2-HG level (Figure 3C). As expected the R132C
mutant produced more 2-HG than R132H mutant.
Also, the other mutants R132G, R132S and R132L all
produced more than R132H. However, the 2-HG con-
centration measured did not exactly correspond to the
KM values determined. The 2-HG concentration from
R100Q was as low as expected, ranging below that from
R132H. To exclude the possibility that the different
2-HG concentrations are due to differential expressiontypes. KM values of IDH1 mutation types for α-ketoglutarate (A) and
s for isocitrate of all IDH1R132 mutations could not be determined.
nificantly different from each other with a p-value of ≤0.01, if
ts were done in triplicate from different protein purifications. D-2-hydro-
ns and wild type IDH1 (C). Levels are measured in cells from one
s of the mutant IDH1 expressing cells are significantly higher (p≤ 0.01)
ficantly higher than the one of R132H (p-value: * = p≤ 0.05 and
2H (p-value: ** = p≤ 0.01).
Pusch et al. Acta Neuropathologica Communications 2014, 2:19 Page 6 of 10
http://www.actaneurocomms.org/content/2/1/19of the respective mutant proteins or different protein sta-
bilities, we performed a western blot demonstrating com-
parable protein quantity (Additional file 3: Figure S5).
Cell viability dependence on 2-HG concentration
Viability upon exogenous exposure to 2-HG was tested
using immortalized human astrocytes, HEK293T cells,
and seven glioma lines (LN18, LN229, LN319, A172,
U87, U373, T98G) by addition of cell permeable octyl-2-
HG to medium [12]. To determine the concentration
range to be used, we calculated the molar 2-HG concen-
trations in the tumor specimens from previous reports
[17,18] and our tumor material. For converting concen-
trations given in μmol/g to molarities we assumed brain
tumor tissue density to be similar to normal human
brain tissue measuring 1.054 +/− 0.014 g/cm3 [19]. On
this basis, 2-HG concentrations in brain tumor tissues
range from 0.1–126 mM. We, therefore, added cell per-
meable octyl-2-HG to cell medium in concentrationsFigure 4 D-2-hydroxyglutarate toxicity and analysis of two LN229 sub
lines (A). D-2-hydroxyglutarate mediated toxicity in different cell lines (B). T
numbers in % compared to the corresponding untreated control. D-2-hydr
subclones H3 and H114 overexpressing different protein levels of R132H (C
other (p≤ 0.01). Proliferation of LN229 glioma cell line and of two LN229 g
levels of R132H (D). The relative cell numbers were determined 48 h after s
The enhanced proliferation of subclone H3 is not significant compared to t
statistically significant compared to both other lines (p ≤ 0.01).ranging from 100 μM to 150 mM. All cell lines chal-
lenged perished at 2-HG concentrations of 7.5 mM and
above. Therefore, only data using octyl-2-HG concentra-
tions ranging from 250 μM to 7.5 mM are shown in
Figure 4A.
Due to the high toxicity of octyl-2-HG we switched to
the less cell permeable sodium salt of 2-HG, because we
aimed for more physiological concentrations in our
experiments. We added this 2-HG to HEK293T, human
astrocytes and LN229 in concentrations ranging from
500 μM to 50 mM. Concentrations at the low end from
500 μM to 1 mM had no significant effect on proliferation.
From 2.5 mM to 50 mM, increasing toxicity was observed
with LN229 being more resistant than HEK293T and
human astrocytes (Figure 4B).
In order to test the effect of endogenous 2-HG we trans-
fected LN229 with pDEST26 containing an IDH1R132H
construct. Two clones H3 and H114 were established
by single cell cloning, both stably producing 2-HG, albeitlines. Octyl-D-2-hydroxyglutarate mediated toxicity in different cell
oxicity was measured 48 h after treatment. Plotted are the relative cell
oxyglutarate levels in LN229 glioma cell line and two LN229 glioma cell
). All D-2-hydroxyglutarate levels are significantly different from each
lioma cell subclones H3 and H114 overexpressing different protein
eeding and are plotted in % compared to the corresponding control.
he parental line, but the reduced proliferation of subclone H114 is
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2-HG/μg total protein, a concentration not significantly
affecting proliferation. In fact, a trend for higher prolifera-
tion was noted. In contrast, clone LN229 H114 containing
13.94 pmol 2-HG/μg total protein exhibited a significant
reduction of proliferation (Figures 4D).
Concentration dependent toxicity of different IDH1
mutations
We transfected in LN319 and HEK293T cells with
pcDNA6/TR and selected single colonies. This was done to
have cell lines with high expression of TR (tet repressor)
sufficient for silencing pT-Rex-DEST30 prior to induction
with Doxycycline.
We cloned IDH1 wt, all the R132 mutants and the
R100Q mutant in pT-Rex-DEST30, and transfected these
constructs into LN319 and HEK293T containing pcDNA6/
TR. Then, the expression of the respective mutant IDH
protein was induced.
Induction of R132H had no effect on proliferation in
LN319, but in HEK293T it lead to a reduction in growth.
Induction of all the mutations with lower KM for α-KG re-
sulted in reduced cell growth in both lines. As expected,
expression of the R100Q mutation, producing low levels of
2-HG, also had no effect on growth in LN319. Neither ex-
pression of wt IDH1 protein nor of GFP affected cell
growth in LN319. Results of growth kinetics for the differ-
ent transfectants are shown in Figure 5.
Effect of 2-HG concentration on migration and colony
formation
Wound healing assays were performed employing LN229
and different concentrations of 2-HG. In addition, weFigure 5 Proliferation analysis of LN319 glioma and HEK293T cells wi
of LN319 glioma and HEK293T cells bearing tetracycline inducible construc
are the relative cell numbers compared to the corresponding uninduced c
corresponding to their p-values (* = p≤ 0.05 and ** = p≤ 0.01).performed this assay employing LN229 H3 and LN229
H114 cells with ectopic expression of mutant R132H IDH
protein at different levels. Addition of 2-HG at low con-
centration of 100 μM resulted in enhanced migration,
which was less pronounced at higher concentrations of
10 mM. LN229 H3 showed a migration rate higher than
the parental LN229 while LN229 H114 did not differ from
LN229 in this respect (Figure 6A).
Colony formation in soft agar was augmented upon
exposure to 2-HG in moderate concentrations. Concen-
trations of 100 μM and 10 mM 2-HG in medium both
resulted in an increase of colonies by 61% and 59%,
respectively. LN229 H3 containing 6.58 pmol 2-HG/μg total
protein exhibited a 3-fold increase in colony formation. In
contrast, LN229 H114 containing 13.94 pmol 2-HG/μg
total protein did not form significantly more colonies than
LN229 without treatment (Figure 6B).
Discussion
The IDH1 mutation of the R132H type by far outnum-
bers the other IDH1 mutations in diffuse astrocytic and
oligodendroglial tumors. In order to provide a hypoth-
esis for this lopsided distribution, we characterized bio-
chemical features of different IDH1 mutations, analyzed
native tumors and performed experiments addressing
the effects of different mutations on in vitro systems.
Common to all IDH1 mutations is acquisition of a neo-
enzymatic activity with the ability to convert α-KG to
2-HG. Thus, we determined the Michaelis constants of
mutated IDH proteins for the substrate α-KG. We de-
tected the highest KM for α-KG in protein carrying the
R132H mutation followed by R132G, R132C, R132S and
R132L (Figure 3). While increased 2-HG levels areth and without induction of mutant IDH expression. Cell viability
ts of different IDH mutations and controls 72 h after induction. Shown
ontrols. The significant differences are depicted in the figure with their
Figure 6 Migration and soft agar analysis of LN229 treated with D-2-hydroxyglutarate and LN229 subclones. Migration of LN229 and
subclones H3 and H114 after 72 h. LN229 cells were treated with 100 μM or 10 mM 2-HG. Subclones H3 and H114 expressed R132H protein in
different amounts (A). Plotted is the open area after 24 h of incubation. Treatment with 100 μM 2-HG or ectopic expression of low amounts of
R132H protein (subclone H3) increased migration speed significantly (** = p≤ 0.01). Colony formation in soft agar of the same cells in the same
setting (B). Shown are the relative colony numbers compared to the untreated parental line (100%). The 2-HG treatment could significantly
(* = p≤ 0.05) increase colony formation independent of the used concentration. An even stronger increase (** = p≤ 0.01) could be measured
for subclone H3, but no difference could be detected for subclone H114.
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cells, it should be kept in mind that high 2-HG levels may
be toxic. Thus, positive discrimination for a mutation type
resulting in a protein with moderate activity for features
beneficial at low but potentially deleterious at high dose is
well compatible with a selection process.
A beneficial effect of moderately increased 2-HG on
proliferation (cell line LN229 H3, 6.58 pmol 2-HG/μg
total protein) is demonstrated in Figure 4D. In contrast,
strongly increased 2-HG levels (cell line LN229 H114,13.94 pmol 2-HG/μg total protein) did not favor prolifera-
tion. Similarly, migration could be increased for LN229 by
100 μM 2-HG in the medium and slightly less by 10 mM
2-HG in the medium. Moreover, the cell line LN229 H3
with moderately induced 2-HG production exhibited in-
creased migration compared to LN229. LN229 H114, with
higher 2-HG production, did not migrate significantly fas-
ter than LN229 (Figure 6A). Likewise, colony formation
was strongly supported by moderate 2-HG concentrations
in the LN229 and subclone LN229 H3. In contrast, LN229
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(Figure 6B).
To test the effect of 2-HG on viability of cells we added
2-HG, or the more cell permeable octyl-2-HG [12], to cul-
ture medium. In our models employing human astrocytes
and HEK293T, LD50 for 2-HG was determined for con-
centrations between 5 mM and 10 mM while the LD50 for
LN229 was approximately 50 mM (Figure 4B). In the same
cell lines and several more, the LD50 for octyl-2-HG was
reached at approximately 750 μM (Figure 4A). Moreover,
transfection and induction of the different IDH1 muta-
tions into LN319 cells demonstrated no influence on pro-
liferation for R132H; however, the other mutations with
lower KM for α-KG inhibited proliferation. These findings
demonstrated considerable cell toxicity of 2-HG.
To further support this hypothesis we analyzed the
amount of 2-HG in formalin fixed and paraffin embed-
ded brain tumors harboring different IDH mutations.
The limiting step of our analyses was the low incidence
of IDH1 mutations other than R132H in gliomas. The
detection of moderately increased 2-HG levels in tumors
with the IDH1R132H mutation and higher levels in the
rare mutation types matched well with the different af-
finities for α-KG of the respective mutations.
Thus, in glioma cells we demonstrate beneficial effects
of moderate 2-HG concentrations for proliferation,
migration and colony formation and toxic effects on these
readouts for high 2-HG concentrations. This would well
match a model favoring an IDH1 mutation with an inter-
mediate KM for α-KG.
These findings may explain the strong preponderance
of the IDH1R132H mutation type in glioma.
Both exo- and endogenous mechanisms affect types of
mutation in DNA. Sporadic primary brain tumors in
humans have not been shown to be associated with typical
exogenous DNA damage such as ultraviolet-induced
DNA-damage or that following exposure to carcinogens.
It is unresolved whether accumulation of distinct muta-
tions such as IDH1 originates from an endogenously
mediated increase or a specific failure of repairing this dis-
tinct alteration. In low grade glioma, cytosine to thymidine
transitions constitute the most frequent mutation type on
the single nucleotide level [20]. R132H facilitated by a
CGT to CAT change corresponds to a C to T transition
on the reverse strand. On the other hand, R132C facili-
tated by CGT to TGT is based on this transition on the
coding strand. Neglecting potential repair of the C to T
transition on the reverse strand during replication, R132H
and R132C could be expected to occur with comparable
frequency. This holds true for these mutations in acute
myeloid leukemia [5,21]. In contrast, IDH1R132H domi-
nates in diffuse gliomas and R132C appears to be the most
frequent mutation in chondrosarcoma [6,7] and intrahepa-
tic cholangiocarcinoma [8,22]. Thus, the strong bias forIDH1R132H mutation in astrocytoma and oligodendrogli-
oma may support a selection bias for this alteration.Conclusion
We determined significantly different enzymatic activities
for distinct IDH1 mutations and provide a selection based
hypothesis for the preponderance of the IDH1R132H
mutation in astrocytoma and oligodendroglioma.Additional files
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